Jiangsu Hengrui Pharmaceuticals Co., Ltd. (“HENGRUI PHARMA”, stock code: 01276.HK), a benchmark enterprise in China's pharmaceutical industry and a globally leading innovative pharmaceutical company, completed its IPO and listing on the Main Board of Hong Kong Stock Exchange On May 23, 2025. This milestone marks the company’s establishment of a dual capital market presence (“A+H”) listing 25 years after its initial A-share IPO.

As the PRC legal counsel to the underwriter, Jingtian & Gongcheng has provided legal services for the listing throughout the whole process—from application submission to successful listing—in under five months. Our expertise earned high praise from the client and intermediary teams.